A Five Immune-Related IncRNA Signature as a Prognostic Target for Glioblastoma

Xiaomeng Li¹, Li Sun¹, Xue Wang¹, Nan Wang¹, Kanghong Xu¹, Xinquan Jiang¹* and Shuo Xu²,³*

¹School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, China, ²Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China, ³Brain Science Research Institute, Shandong University, Jinan, China

Background: A variety of regulatory approaches including immune modulation have been explored as approaches to either eradicate antitumor response or induce suppressive mechanism in the glioblastoma microenvironment. Thus, the study of immune-related long noncoding RNA (IncRNA) signature is of great value in the diagnosis, treatment, and prognosis of glioblastoma.

Methods: Glioblastoma samples with IncRNA sequencing and corresponding clinical data were acquired from the Cancer Genome Atlas (TCGA) database. Immune-IncRNAs co-expression networks were built to identify immune-related IncRNAs via Pearson correlation. Based on the median risk score acquired in the training set, we divided the samples into high- and low-risk groups and demonstrate the survival prediction ability of the immune-related IncRNA signature. Both principal component analysis (PCA) and gene set enrichment analysis (GSEA) were used for immune state analysis.

Results: A cohort of 151 glioblastoma samples and 730 immune-related genes were acquired in this study. A five immune-related IncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCQ-AS1) was identified. Compared with patients in the high-risk group, patients in the low-risk group showed a longer overall survival (OS) in the training, validation, and entire TCGA set (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, respectively). Additionally, the survival prediction ability of this IncRNA signature was independent of known clinical factors and molecular features. The area under the ROC curve (AUC) and stratified analyses were further performed to verify its optimal survival predictive potency. Of note, the high-and low-risk groups exhibited significantly distinct immune state according to the PCA and GSEA analyses.

Abbreviations: AUC, area under curve; CI, confidence intervals; FDR, false discovery rate; GSEA, gene set enrichment analysis; HR, hazard ratio; IDH, isocitrate dehydrogenase; KPKM, fragments per kilobase of exon model per million mapped; KPS, Karnofsky performance score; IncRNA, long noncoding RNA; MGMT, O6-methylguanine-DNA methyltransferase; NES, normalized enrichment score; OS, overall survival; PCA, principal component analysis; ROC, receiver operating characteristic; TCGA, the Cancer Genome Atlas.
Conclusions: Our study proposes that a five immune-related lncRNA signature can be utilized as a latent indicator of prognosis and potential therapeutic approach for glioblastoma.

Keywords: glioblastoma, long non-coding RNA, immune, signature, prognostic

INTRODUCTION

Glioblastoma is the most prevalent and fatal primary brain tumor around the world (McGuire, 2016). Even given the optimal therapeutic approaches combined with surgical resection, targeted radiotherapy, high-dose chemotherapy as well as novel electric field treatment, the median overall survival (OS) is still less than 21 months (Tan et al., 2020; Delgado-Martín and Medina, 2020; Stupp et al., 2017). In the past decades, seminal discoveries have clarified the mechanism of immune response within glioblastoma, and emerging immune therapeutic strategies have exhibited great potential by initiating and amplifying host anti-tumor immunity (Turkowski et al., 2018; Silver et al., 2016; Sampson et al., 2017). However, glioblastoma can hardly be eradicated due to profound tumor-mediated immunosuppression (Jackson et al., 2019; McGranahan et al., 2019). Therefore, immune-related biomarkers of this malignancy do not facilitate the diagnosis and prognosis evaluation but rather offer an extraordinary glimpse of the tumor pathophysiology.

Long noncoding RNA (lncRNA), of which length ≥ 200 bp, exhibited a wide range of regulatory activities without protein-coding capacity (Kopp and Mendell, 2018). Abundant evidence has demonstrated that lncRNAs were extensively expressed in various tumors and involved in tumorigenesis, tumor progression, infiltration, and metastasis (Bhan et al., 2017; Li et al., 2018b; Jiang et al., 2019). In glioblastoma, lncRNA MALAT1 contributes to tumor proliferation and progression by MALAT1/miR-199a/ZHX1 axis (Liao et al., 2019). HOTAIR1M1 promotes glioblastoma growth and invasion by up-regulating HOX1 Gene (Li et al., 2018a). ADAMTS9-AS2 triggers temozolomide resistance via upregulating the FUS/MDM2 axis in glioblastoma cells (Yan et al., 2019). Meanwhile, lncRNAs also play a vital role in immune regulation (Chen et al., 2017; Wang et al., 2019b). For instance, Lnc-EGFR generates immunosuppressive status in patients with hepatocellular carcinoma by facilitating regulatory T cell differentiation (jiang et al., 2017). Lnc-BH3I40-ASI promotes the development of early breast cancer by regulating STAT3 signaling and builds an immune-permissive microenvironment (DeVaux et al., 2020). Until recently, it was reported that certain immune-related lncRNA signature has predictive potential for the survival of glioma patients (Xia et al., 2020; Tian et al., 2020; Wang et al., 2020), indicating that lncRNAs also participate in the glioma-mediated immune dysregulation within the blood-brain barrier. Nevertheless, the connection between immune-related lncRNAs and prognosis prediction of glioblastoma is worth further exploration.

In the present study, we took advantage of the Cancer Genome Atlas (TCGA) database to establish an immune-related lncRNA signature for glioblastoma patients, which might act as a key prognosis predictor and promising immunotherapeutic targets for this malignancy.

MATERIALS AND METHODS

Data Source

Normalized RNA-seq data with the estimation of Fragments Per Kilobase of exon model per Million mapped fragments (FPKM) of glioblastoma patients and the corresponding clinical information were acquired from TCGA database (https://portal.gdc.cancer.gov/, RRID: SCR_003193). The exclusion criteria were as follows: 1) samples with unknown survival information; 2) samples with OS less than 30 days, who died because of nonneoplastic factors, such as myocardial infarction, hemorrhage, and severe infection (Cheng et al., 2015; Li and Guo, 2020). A total of 151 TCGA glioblastoma samples were included for the subsequent analysis, that were randomly split up into the training set and the validation set. The training set with 76 samples were used to construct the prognosis model. The validation set with 75 samples and the entire TCGA set were then applied to check the results of the training set. The IRB approval and the documentation of informed consent are waived, because all the data acquired from the TCGA database are open to the public.

Immune-Related lncRNAs

Immune-associated genes associated with glioblastoma were downloaded from the Molecular Signatures Database v7.0 (Immune system process M13664, Immune response M19817, https://www.gsea-msigdb.org/gsea/msigdb/index.jsp, RRID: SCR_016863) (Cheng et al., 2016). In total, 322 immune-related genes were extracted after integration (Subramanian et al., 2005; Cheng et al., 2016). 730 immune-related lncRNAs were then determined based on immune-lncRNAs co-expression network and Pearson correlation analysis (|R| > 0.5, FDR < 0.001).

Signature Construction

Univariate cox regression analysis was used to identify lncRNAs that were significantly associated with prognosis (p < 0.01). Stepwise multivariate Cox regression analysis was employed to develop a risk score. The purpose of the risk score is to determine a uniform signature for subsequent prognostic prediction. The risk score formula was as follows (Cheng et al., 2015; Yang et al., 2019):

\[
\text{Risk score} = \beta_{\text{gene1}} \times \text{expr}_{\text{gene1}} + \beta_{\text{gene2}} \times \text{expr}_{\text{gene2}} + \cdots + \beta_{\text{genem}} \times \text{expr}_{\text{genem}}.
\]
**RESULTS**

**Immune-Related lncRNAs in Glioblastoma**

322 immune-related genes associated with glioblastoma were downloaded from the Molecular Signatures Database. 730 immune-related lncRNAs were then acquired by immune-lncRNAs co-expression networks and Pearson correlation analysis (|R| > 0.5, FDR < 0.001; Supplementary Figure S1A). 151 TCGA glioblastoma patients were divided into the training set (n = 76) and the validation set (n = 75) randomly and equally. Demographic and clinical features were briefly shown in Supplementary Table S1. Univariate Cox proportional hazards regression analysis was implemented in the training set to screen out the lncRNAs with significant prognostic values. A total of 15 immune-related lncRNAs were identified to correlate to the glioblastoma patients’ survival (p < 0.01) and then enrolled into the candidate pool for further analysis. Finally, 5 out of 15 candidate lncRNAs were selected through multivariate Cox proportional hazards regression as independent prognostic factors (Table 1). Among these immune-related lncRNAs, 4 lncRNAs (AC046143.1, AC021054.1, AC080112.1, MIR222HG) were categorized as deleterious factors on the basis of their β value, whereas PRKCQ-AS1 tended to be protective and its high expression was associated with longer survival. Immune-lncRNAs co-expression networks were further assessed as shown in Supplementary Figure S1B.

**Construction and Verification of Prognostic Risk Model**

We hereby employed a risk score approach to construct a five immune-related lncRNA signature (Cheng et al., 2015; Kiran et al., 2019; Gao et al., 2018). With the median risk score as a cut-off value, the signature was verified in the validation set and the entire TCGA set.

---

**TABLE 1** | Five lncRNAs selected as prognosis-associated factors.

| Ensembl database ID | Gene symbol | HR  | 95% CI        | p value | β value |
|---------------------|-------------|-----|---------------|---------|---------|
| ENSG00000229334.1   | AC046143.1  | 2.183 | 1.329–3.587   | 2.04E-03 | 0.781   |
| ENSG00000177406.4   | AC021054.1  | 2.242 | 1.457–3.449   | 2.39E-04 | 0.807   |
| ENSG00000268208.1   | AC080112.1  | 1.672 | 1.224–2.284   | 1.25E-03 | 0.514   |
| ENSG00000270069.1   | MIR222HG    | 2.060 | 1.361–3.073   | 4.00E-04 | 0.723   |
| ENSG00000237943.5   | PRKCQ-AS1   | 0.537 | 0.341–0.845   | 7.20E-08 | -0.621  |

**FIGURE 1** | Kaplan-Meier survival curve analyses of OS in high-(red curve) and low-risk (blue curve) group for the training set (A), the validation set (B) and the entire TCGA set (C). OS, overall survival.
cut-off value, samples in the training set of glioblastoma patients were divided into high-(n = 38) and low-risk (n = 38) groups. There was a significant difference in OS between the two groups. Patients with high-risk displayed reduced OS in contrast to those with low-risk (median OS: 0.986 vs 1.488 years, p = 1.931e-05, Figure 1A). To confirm the predictive performance, the identical algorithm and coefficient were then employed in the validation and entire TCGA set, and similar results were obtained from both sets (median OS: 0.903 vs 1.244 years, P = 0.017; median OS: 0.939 vs 1.457 years, p = 3.397e-06; Figures 1B,C).

As shown in Figure 2A, the risk scores of glioblastoma patients in the training set were sorted, and their survival status were plotted in dot graph. The heat map generated based on the RNAseq data exhibited the distributed expression modes of lncRNA among the two groups. For samples with low risk, the deleterious lncRNAs had relatively low expression except for the protective PRKCQ-AS1, which were opposite to the high-risk samples. Distribution tendency among age, treatment options, and molecular features was also conducted. Similar findings were confirmed in the validation set and entire TCGA set (Figures 2B,C). The detailed immune-related lncRNA expression was shown in Supplementary Figure S2.

FIGURE 2 | Risk score distribution, survival status, expression of lncRNA, as well as distributed patterns of clinical and molecular characteristics for glioblastoma patients in the training set (A), the validation set (B) and the entire TCGA set (C).

The Prognostic Independence of the Five Immune-Related lncRNA Signature

Univariate and multivariate Cox regression analyses were performed to validate whether this five-lncRNA signature along with the other clinicopathological factors were independent prognostic indicators of the glioblastoma patients. As a result, the prognostic independence of the lncRNA signature was proven for OS in the entire TCGA set (HR = 1.324, p = 1.26e-05, Table 2). Analogously, age (HR = 2.267, p = 0.001), radiotherapy (HR = 0.332, p = 5.42e-05) and chemotherapy (HR = 0.419, p = 6.64e-04) were also demonstrated to be independent prognostic factors.

In addition, the prognostic independence of this five-lncRNA signature was evaluated to certain well-known molecular features of glioblastoma. Unsurprisingly, multivariate Cox regression analysis validated its statistical robustness considering the
**IDH1** mutation and *MGMT* promoter methylation status (HR = 1.386, *p* = 3.14e-06, Supplementary Table S2). Moreover, *IDH1* mutation status was also obviously related to OS (HR = 0.336, *p* = 0.039).

**Identification of Predicting Performance of the Five Immune-Related IncRNA Signature**

The AUCs were employed to evaluate the predictive accuracy of the prognostic indicator demonstrated by multivariate regression analysis, including age, radiotherapy, chemotherapy, and the immune-related IncRNA signature. The IncRNA signature curve (AUC = 0.671) was higher than that of age (AUC = 0.540), radiotherapy (AUC = 0.565), and chemotherapy (AUC = 0.563) at 1-year OS (Figure 3A). Similar results were demonstrated at 2-year OS (LncRNA signature AUC = 0.809; age AUC = 0.628; radiotherapy AUC = 0.525; chemotherapy AUC = 0.488; Figure 3B). Moreover, we identified its predictive power contrasted to *IDH1* and *MGMT* promoter status. Again, the immune-related IncRNA signature curve showed the greatest AUC value over *IDH1* mutation curve and *MGMT* promoter methylation curve at 1-year OS (IncRNA signature AUC = 0.587; *IDH1* AUC = 0.494; *MGMT* AUC = 0.514; Figure 3C) and 2-year OS (IncRNA signature AUC = 0.728; *IDH1* AUC = 0.514; *MGMT* AUC = 0.486; Figure 3D).

The signature we present, to the best of our knowledge, is the first immune-related IncRNA signature for glioblastoma based on the construction of immune-IncRNAs co-expression networks. However, several other immune-associated signatures have been reported recently to predict the prognosis of glioblastoma patients, including a gene signature reported by Cheng et al. (hereinafter referred to as ChengSig) (Cheng et al., 2016) and a lncRNA signature proposed by Zhou et al. using survival analysis and Cox regression model (hereinafter referred to as ZhouSig) (Zhou et al., 2018). Therefore, we compared the prognostic abilities of our lncRNA signature (hereinafter referred to as LncSig) and the immune-related signature mentioned above. Utilizing the same TCGA patient cohort, LncSig had a better predictive performance at 1-year OS (LncSig AUC = 0.666; ChengSig AUC = 0.570; ZhouSig AUC = 0.610; Figure 3E) and 2-year OS (LncSig AUC = 0.796; ChengSig AUC = 0.619; ZhouSig AUC = 0.646; Figure 3F). In addition, there are several similar immunologically-irrelevant, with which we have also compared, including Zhang (hereinafter referred to as ZhangSig) (Zhang et al., 2013) and Li’s IncRNA prognostic signature (hereinafter referred to as LiSig) (Li et al., 2019) for glioblastoma and Pan’s signature (hereinafter referred to as PanSig) (Pan et al., 2020) for glioma. Within the same patient cohort, our signature had a better predictive performance at 1-year OS (LncSig AUC = 0.666; ZhangSig AUC = 0.521; LiSig AUC = 0.563; PanSig AUC = 0.491; Supplementary Figure S3A) and 2-year OS (LncSig AUC = 0.796; ZhangSig AUC = 0.548; LiSig AUC = 0.590; PanSig AUC = 0.573; Supplementary Figure S3A).

These data indicated the predictive power of the five immune-related IncRNA signature for the prognosis assessment of glioblastoma.

**Application of the IncRNA Signature in Stratified Groups**

To assess the feasibility of this immune-related signature, the glioblastoma patients were further categorized into different stratified groups based on their age, sex, KPS score, radiotherapy and chemotherapy status. Within each group, samples were divided into high- and low-risk groups.

### Table 2: Univariate and Multivariate Cox regression analysis of overall survival of GBM patients.

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | HR                  | 95% CI of HR          | *p* value     | HR                  | 95% CI of HR          | *p* value     |
| Training set (n = 76) | | | | | | |
| Five-lncRNA signature (high/low) | 1.506 | 1.278–1.776 | 1.08e-06 | 1.385 | 1.159–1.654 | 3.38e-04 |
| Age (>50/≤50) | 2.739 | 1.190–6.304 | 0.018 | 2.549 | 1.103–5.891 | 0.029 |
| Gender (male/female) | 0.678 | 0.377–1.220 | 0.195 | 0.721 | 0.396–1.317 | 0.288 |
| KPS (>70/≤70) | 0.404 | 0.175–0.936 | 0.035 | 0.396 | 0.164–0.957 | 0.04 |
| Radiotherapy (yes/no) | 0.288 | 0.132–0.631 | 0.002 | 0.274 | 0.124–0.605 | 0.001 |
| Chemotherapy (yes/no) | 0.258 | 0.120–0.556 | 5.41e-04 | 0.269 | 0.124–0.581 | 8.37e-04 |
| Valuation set (n = 76) | | | | | | |
| Five-lncRNA signature (high/low) | 1.695 | 1.194–2.409 | 0.003 | 1.579 | 1.092–2.282 | 0.015 |
| Age (>50/≤50) | 1.034 | 1.009–1.059 | 0.008 | 1.028 | 1.003–1.054 | 0.027 |
| Gender (male/female) | 0.972 | 0.561–1.686 | 0.92 | 1.106 | 0.623–1.962 | 0.731 |
| KPS (>70/≤70) | 0.995 | 0.982–1.008 | 0.443 | 0.992 | 0.979–1.006 | 0.283 |
| Radiotherapy (yes/no) | 0.288 | 0.132–0.631 | 0.002 | 0.274 | 0.124–0.605 | 0.001 |
| Chemotherapy (yes/no) | 0.553 | 0.280–1.094 | 0.089 | 0.590 | 0.294–1.182 | 0.137 |
| Entire TCGA set (n = 151) | | | | | | |
| Five-lncRNA signature (high/low) | 1.425 | 1.269–1.601 | 2.12e-09 | 1.324 | 1.167–1.501 | 1.26e-05 |
| Age (>50/≤50) | 2.388 | 1.447–3.940 | 6.06e-04 | 2.267 | 1.370–3.750 | 0.001 |
| Gender (male/female) | 0.828 | 0.558–1.230 | 0.35 | 0.961 | 0.640–1.445 | 0.85 |
| KPS (>70/≤70) | 0.992 | 0.982–1.002 | 0.116 | 0.991 | 0.981–1.002 | 0.096 |
| Radiotherapy (yes/no) | 0.289 | 0.169–0.492 | 5.17e-06 | 0.332 | 0.194–0.567 | 5.42e-05 |
| Chemotherapy (yes/no) | 0.406 | 0.246–0.668 | 3.97e-04 | 0.419 | 0.254–0.692 | 6.64e-04 |
utilizing the five immune-related lncRNA signature. As shown in Figures 4A–G, patients with lower risk exhibited survival preference in most stratified cohorts consistently, including age ≤ 50 (n = 36, p = 3.841e-04), age > 50 (n = 115, p = 1.313e-04), male (n = 97, p = 3.678e-04), female (n = 54, p = 5.655e-03), high KPS (KPS score > 70, n = 83, p = 6.064e-05), radiotherapy (n = 126, p = 2.041e-06) and chemotherapy (n = 112, p = 1.228e-06).

Survival analysis also indicated that the patients in the high-risk group had shorter survival in the stratified cohorts of wild-type IDH1 (n = 136, p = 4.039e-06), methylated (n = 52, p = 3.862e-02), and unmethylated MGMT promoter (n = 73, p = 2.229e-03) in Figures 4H–J. These results suggested that this signature acted as a consistently reliable indicator in the assessment of clinical outcomes of glioblastoma patients.
Immune Status Associated with the lncRNA Signature

PCA was conducted to investigate the different distributions based on immune genes and whole-gene expression patterns (Figures 5A,B). The results displayed that the high- and low-risk group tended to be distributed in different directions, indicating that the high-risk group had significant differences in the immune status from the low-risk group. Functional enrichment analysis was then conducted via GSEA (Subramanian et al., 2005; Cheng et al., 2016; Wang et al., 2018). As showed in Figures 5C,D, immune system process and immune response pathways were annotated in the high-risk group in comparison with in the low-risk group. Consequently, there is a close correlation between the signature and the immune status within the glioblastoma environment.

DISCUSSION

The outcomes for patients with glioblastoma are miserable nowadays, which arouse great efforts to investigate the pathophysiological mysteries of this malignancy. In the past decades, convergent evidence has highlighted that the central nervous system is immunologically distinct rather than privileged (Ransohoff and Engelhardt, 2012; Kipnis, 2016; Engelhardt et al., 2017). However, redundant immunosuppressive mechanisms within the glioblastoma inhibit the anti-cancer immune responses and harness them with tumor-promoting characteristics (Lamano et al., 2019; Tomaszewski et al., 2019). The lncRNA dysregulation has been widely reported in various tumors including glioblastoma (Wang et al., 2019a; Zhuang et al., 2019; Ji et al., 2019). For instance, lncRNA MIR155HG was observed that not only associates with poorer OS in glioblastoma but also significantly correlates with infiltrating levels of immune cells and immune molecules (Peng et al., 2019). Consequently, it is necessary for us to study the diagnostic and prognostic values of immune-related lncRNAs for glioblastoma.

In the present study, 151 glioblastoma samples from the TCGA database were enrolled. Immune-lncRNAs co-expression networks and Pearson correlation analysis were conducted to acquire 730 immune-related lncRNAs. A five immune-related lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCQ-AS1) was then developed to classify glioblastoma patients into the high- and low-risk group. Glioblastoma patients in the low risky group showed longer survival time than those in high risky group (p = 1.931e-05, p = 1.706e-02, and p = 3.397e-06, Figure 1). Univariate and multivariate Cox regression analyses further validated the prognostic effect of this five immune-related lncRNA signature,
even considering key interference factors such as age, gender, KPS score, radiotherapy, chemotherapy, and molecular features (Table 2; Figure 2). Of note, the AUC of the lncRNA ROC curve was greater than those of any other significant prognostic indicator (Figure 3). Furthermore, this immune-related lncRNA signature consistently discriminated the low risky patients with statistical survival preferences in the most stratified cohorts (Figure 4). Finally, we discovered differences in the immune status associated with the lncRNA signature. Specifically, the samples with high risk tended to display more concentrated immune properties (Figure 5). These findings indicate that this immune-related signature exhibits a vital prognostic effect for glioblastoma.

The mechanisms underlying lncRNA regulation of immune response remain unknown. Among these five enlisted lncRNAs, PRKCQ-AS1 acts as a protective player, and its high expression is relevant to longer survival. Interestingly, it has been reported that PRKCQ-AS1 was upregulated in colorectal cancer and associated with reduced survival in colorectal cancer (Shademan et al., 2019), suggesting the complexity and heterogeneity of tumor biology. In contrast, ACO46143.1, ACO21054.1, ACO80112.1, and MIR222HG were associated with poor prognosis. There have been quite few studies focusing on these lncRNAs, except that MIR222HG expression facilitated the development of castration-resistant prostate cancer (Sun et al., 2018). There were no reports that these identified lncRNAs harbor any immune-related yet; however, immune-lncRNAs co-expression networks in this study indicate that they may regulate immune function either directly or indirectly. For instance, ACO21054.1 was shown to be correlated to dozens of downstream genes, which involve the regulations of chemotaxis (CXC2R, CCR5, CCR1, CXCL12) (Gouwy et al., 2014), immune cell infiltration (ITGB2) (Xiu et al., 2020) and phenotype polarization (IL10, IL27RA) (Cox et al., 2011). In addition, we investigated the correlation between these lncRNAs and immune stimulatory molecules with available TCGA data, including CTLA4, PDL1, TIM-3, and B7-H3. Interestingly, ACO46143.1 was positively correlated with B7-H3, while the protective factor PRKCQ-AS1 was negatively correlated with B7H3. ACO21054.1 was positively correlated with CTLA4 and TIM-3, and MIR222HG was also positively correlated with B7-H3 and PDL1 (Supplementary Figure S4). Moreover, although these lncRNAs are dominantly expressed by glioblastoma, exosomal lncRNA has become elucidated as a key mechanism to abort anti-tumor immunity and induce immunosuppression (Tielking et al., 2019). Thus, our findings could propose several potential lncRNA targets for glioblastoma immunotherapy.

Wang et al. reported a nine immune-related lncRNA signature for patients with anaplastic gliomas, a less malignant form of brain tumor (Wang et al., 2018). Li and Meng also developed an eight immune-related lncRNA signature associated with low-grade glioma prognosis (Li and Meng, 2019). However, these identified lncRNAs are not coincidental with our signature. There could be several reasons. First, their data source and bioinformatic process are quite different. For example, Wang et al. obtained the data from the Chinese Glioma Genome Atlas.
(CGGA) microarray data, and then validated their findings in two additional datasets (GSE16011, REMBRANDT) but not TCGA as we conducted. Second but more important, all these works, including ours, confirm the complexity of glioma immunity, considering the inconsistent tumorigenesis and regulation characteristics between different histological classifications of gliomas. Meanwhile, Zhou et al. demonstrated that a six-lncRNA signature which improved prognosis prediction was immune-related based on the TCGA data, whose methodology was quite opposite to ours (Zhou et al., 2018). More specifically, they identified their lncRNA signature via Cox regression, and then suggested their signature might be relevant to the immune processes and pathways with in silico functional analysis. In contrast, we screened out the immune-associated lncRNAs by co-expression networks at the beginning, and then identified five lncRNAs with significant prognostic power using a risk score method. Despite the different methodologies, manipulation of glioblastoma immune by various lncRNAs can be demonstrated consistently (Boussiotis and Charest, 2018; Vinay et al., 2015).

Our study has some limitations. First, our lncRNA signature was based on glioblastoma samples acquired from the TCGA data portal. Validation using non-TCGA data, such as CGGA and REMBRANDT, could bring more conviction theoretically; however, it was with considerable difficulty currently because the lncRNA-seq profiling and clinical data varied among different datasets. For instance, the expression profiling of AC046143.1 was not available in CGGA and REMBRANDT. Second, it’s well-documented that multiple infiltrating immune cells as well as intrinsic tumor cells induce local immune suppression synergistically (Farhood et al., 2019; Heymann and Tacke, 2016). Therefore, it’s urgent to understand how these lncRNAs which are dominantly expressed by glioblastoma modify the phenotype and function of immune cells in the tumor microenvironment. Third, the regulatory mechanisms of these lncRNAs remain largely unknown nowadays. The immune-lncRNAs co-expression network sheds some light on understanding the interactions with some key immune elements; however, the interpretation of this finding should be cautious and further experimental investigation and verification would be necessary. Therefore, we need to conduct further experiments to study the regulatory mechanism of the five lncRNAs in modulating the immune microenvironment within glioblastoma. Despite the limitations mentioned above, our study proposes the very first immune-associated lncRNA signature as a latent prognostic indicator and potential therapeutic approach for glioblastoma.

In conclusion, we identified and verified a five immune-related lncRNA signature (AC046143.1, AC021054.1, AC080112.1, MIR222HG, and PRKCCQA-S1) which had independent prognostic value for patients with glioblastoma. Therefore, we hope it might be utilized as a potential prognostic indicator and inspire the new immunotherapeutic approach.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

XL designed the study, performed the data analysis and wrote the manuscript. LS, XW, NW, KX acquired the data and carried out the bioinformatic analysis. XJ designed the study and the manuscript. SX designed and supervised the study and conducted the final approval of the manuscript. All authors reviewed the manuscript.

FUNDING

This paper was funded by National Natural Science Foundation of China (81502164), Taishan Scholarship Young Expert Program (tsq201909174), Shandong Provincial Natural Science Foundation, China (BS2015Y004) and Department of Science and Technology of Shandong Province (2016GSF201055).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2021.632837/full#supplementary-material.

REFERENCES

Bhan, A., Soleimani, M., and Mandal, S. S. (2017). Long noncoding RNA and cancer: a new paradigm. Cancer Res. 77, 3965–3981. doi:10.1158/0008-5472.CAN-16-2634
Boussiotis, V. A., and Charest, A. (2018). Immunotherapies for malignant glioma. Oncogene 37, 1121–1141. doi:10.1038/s41388-017-0024-z
Chen, Y. G., Satpathy, A. T., and Chang, H. Y. (2017). Gene regulation in the immune system by long noncoding RNAs. Nat. Immun. 18, 962–972. doi:10.1038/nl.2017.77
Cheng, W., Ren, X., Cai, J., Zhang, C., Li, M., Wang, K., et al. (2015). A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget 6, 29285–29295. doi:10.18632/oncotarget.4978
Cheng, W., Ren, X., Zhang, C., Cai, J., Liu, Y., Han, S., et al. (2016). Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology 86, 2226. doi:10.1212/WNL.0000000000002770
Cox, J. H., Kljavin, N. M., Ramamoorthi, N., Diehl, L., Batten, M., and Ghilardi, N. (2011). IL-27 promotes T cell-dependent colitis through multiple mechanisms. J. Exp. Med. 208, 115–23. doi:10.1084/jem.20100410
Delgado-Martin, B., and Medina, M. (2020). Advances in the knowledge of the molecular biology of glioblastoma and its impact in patient diagnosis, stratification, and treatment. Adv. Sci. (Weinh). 7, 1902971. doi:10.1002/advs.201902971
DeVaux, R. S., Ropri, A. S., Grimm, S. L., Hall, P. A., Herrera, E. O., Chittur, S. V., et al. (2020). Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling. J. Cell Biochem. 121, 3465–3478. doi:10.1002/jcb.29621
Wang, X., Yang, J., Guo, G., Feng, R., Chen, K., Liao, Y., et al. (2019b). Novel IncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway. Mol. Cancer 18, 84. doi:10.1186/s12943-019-1013-3

Wang, W., Zhao, Z., Yang, F., Wang, H., Wu, F., Liang, T., et al. (2018). An immune-related lncRNA signature for patients with anaplastic gliomas. J. Neurooncol. 136, 263–271. doi:10.1007/s11060-017-2667-6

Wang, X., Gao, M., Ye, J., Jiang, Q., Yang, Q., Zhang, C., et al. (2020). An immune gene-related five-lncRNA signature for to predict glioma prognosis. Front. Genet. 11, 612037. doi:10.3389/fgene.2020.612037

Xia, P., Li, Q., Wu, G., and Huang, Y. (2020). An immune-related lncrna signature to predict survival in glioma patients. Cell Mol. Neurobiol. doi:10.1007/s10571-020-00857-8

Xiu, M. X., Liu, Z. T., and Tang, J. (2020). Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies. Int. Immunopharmacol. 87, 106827. doi:10.1016/j.intimp.2020.106827

Yan, Y., Xu, Z., Chen, X., Wang, X., Zeng, S., Zhao, Z., et al. (2019). Novel function of IncRNA ADAMTS9-AS2 in promoting temozolomide resistance in glioblastoma via upregulating the FUS/MDM2 ubiquitination axis. Front. Cell Dev. Biol. 7, 217. doi:10.3389/fcell.2019.00217

Yang, B., Shen, J., Xu, L., Chen, Y., Che, X., Qi, X., et al. (2019). Genome-wide identification of a novel eight-lncRNA signature to improve prognostic prediction in head and neck squamous cell carcinoma. Front. Oncol. 9, 898. doi:10.3389/fonc.2019.00898

Zhang, X. Q., Sun, S., Lam, K. F., Kiang, K. M., Pu, J. K., Ho, A. S., et al. (2013). A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol. Dis. 58, 123–31. doi:10.1016/j.nbd.2013.05.011

Zhou, M., Zhang, Z., Zhao, H., Bao, S., Cheng, L., and Sun, J. (2018). An immune-related Six-lncRNA signature to improve prognosis Prediction of glioblastoma multiforme. Mol. Neurobiol. 55, 3684–3697. doi:10.1007/s12035-017-0572-9

Zhuang, C., Ma, Q., Zhuang, C., Ye, J., Zhang, F., and Gui, Y. (2019). lncRNA GClnc1 promotes proliferation and invasion of bladder cancer through activation of MYC. Faseb J. 33, 11045–11059. doi:10.1096/fj.20190078RR

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Sun, Wang, Xu, Jiang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.